Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
NCT06739044 on ClinicalTrials.gov · last registry update 2025-07-28
Finished 11 October 2024, after enrolling 494 people. Primary outcome, as filed: Change in HbA1c from baseline. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 494
- Started
- 2023-09-20
- Primary completion
- 2024-10-11 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in HbA1c from baseline
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.